Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy

Table 1 Baseline characteristics and virological responses at week 48 between groups A and B

	All patients	Group A	Group B	P value
	(n = 231)	(n = 112)	(n = 119)
Age (yr)	32.5 ± 10.1	32.6 ± 9.78	32.5 ± 10.4	0.96
Male (%)	172 (74.4)	83 (74.1)	89 (74.8)	0.99
ALT (IU/L)	113 ± 115	113 ± 117	113 ± 116	0.75
AST (IU/L)	64 ± 74	65 ± 75	62 ± 67	0.74
PLT (× 109/L)	167.7 ± 57.3	170.0 ± 53.9	165.7 ± 60.5	0.56
HBeAg-positive (%)	178 (77.0)	89 (79.5)	89 (74.8)	0.43
HBV DNA at baseline	7.36 ± 1.20	7.38 ± 1.15	7.35 ± 1.25	0.11
(log10 IU/mL)
HBV DNA at week	1.81 ± 0.85	1.74 ± 0.83	1.88 ± 0.87	0.08
48 (log10 IU/mL)
HBV DNA-negative	111 (48.1)	54 (48.2)	56 (47.1)	0.86
(< 20 IU/mL)
HBeAg seroconversion	19 (8.2)	10 (8.9)	9 (7.6)	0.71
in HBeAg-positive patients
ALT normalization	176 (76.2)	85 (75.9)	91 (76.5)	0.91

Group A patients were treated with 0.5 mg/d ETV. Group B patients were treated with 0.5 mg/d ETV maleate. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PLT: Platelet; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.